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Adverse events following immunization
(AEFI)New vaccines designed to prevent diseases endemic in low and middle-income countries (LMICs) are
now being introduced without prior record of utilization in countries with robust pharmacovigilance sys-
tems. To address this deficit, our objective was to demonstrate feasibility of an international hospital-
based network for the assessment of potential epidemiological associations between serious and rare
adverse events and vaccines in any setting. This was done through a proof-of-concept evaluation of
the risk of immune thrombocytopenic purpura (ITP) and aseptic meningitis (AM) following administra-
tion of the first dose of measles-mumps-containing vaccines using the self-controlled risk interval
method in the primary analysis. TheWorld Health Organization (WHO) selected 26 sentinel sites (49 hos-
pitals) distributed in 16 countries of the six WHO regions. Incidence rate ratios (IRR) of 5.0 (95% CI: 2.5–
9.7) for ITP following first dose of measles-containing vaccinations, and of 10.9 (95% CI: 4.2–27.8) for AM
following mumps-containing vaccinations were found. The strain-specific analyses showed significantly
elevated ITP risk for measles vaccines containing Schwarz (IRR: 20.7; 95% CI: 2.7–157.6), Edmonston-
Zagreb (IRR: 11.1; 95% CI: 1.4–90.3), and Enders’Edmonston (IRR: 8.5; 95% CI: 1.9–38.1) strains. A signif-
icantly elevated AM risk for vaccines containing the Leningrad-Zagreb mumps strain (IRR: 10.8; 95% CI:
1.3–87.4) was also found. This proof-of-concept study has shown, for the first time, that an international
hospital-based network for the investigation of rare vaccine adverse events, using common standardized
procedures and with high participation of LMICs, is feasible, can produce reliable results, and has the
potential to characterize differences in risk between vaccine strains. The completion of this network
by adding large reference hospitals, particularly from tropical countries, and the systematic WHO-led
implementation of this approach, should permit the rapid post-marketing evaluation of safety signals
for serious and rare adverse events for new and existing vaccines in all settings, including LMICs.
 2017 World Health Organization. Published by Elsevier Ltd. All rights reserved.ter; FDA,
-income
interval;
ed States.
348 S. Perez-Vilar et al. / Vaccine 36 (2018) 347–3541. Introduction 2.2. Case ascertainment and classificationWith increasing number of vaccine products available, expan-
sion of vaccine manufacturing capabilities, and availability of
new vaccines targeted against diseases highly prevalent in low
and middle-income countries (LMICs) [1], there is a need to
enhance vaccine pharmacovigilance infrastructures globally [2].
Many countries do not have technical capacity and/or large enough
populations to permit the evaluation of rare adverse events
following immunization (AEFI) [2,3]. Enhancement of vaccine
pharmacovigilance capabilities is a key activity for the World
Health Organization (WHO) Global Vaccine Safety Initiative (GVSI)
[4–6]. A previous international pilot study sponsored by WHO and
the Food and Drug Administration (FDA), to evaluate the safety
of the 2009–10 pandemic influenza vaccine, demonstrated
that multinational hospital-based vaccine safety studies were
feasible and could provide a useful framework for the evaluation
of safety concerns [7]. Optimization of operational models,
centralization of case adjudication, improvements in data quality
control, closer supervision of data abstraction, and demonstration
of the feasibility of such international collaborations, with high
participation from LMICs, were identified by WHO as issues to be
resolved [7]. Thus, for a subsequent demonstration project, it was
important to reach higher participation from LMICs, select a
vaccine widely used, and an AEFI that, at least in severe cases,
would require hospitalization [2]. It was also essential to select
an AEFI known to be associated with some of the vaccine strains
being used.
Measles-containing vaccines are live-attenuated, often given in
combination with mumps and rubella vaccines. The first dose is
usually given at one year of age, although it is administered at nine
months of age in countries with ongoing measles transmission [8].
The second dose is either given at 15–18 months of age, at 4–
6 years of age, or in campaigns. Our objective was to demonstrate
feasibility of an international hospital-based network for assessing
epidemiological associations between serious and rare adverse
events and vaccines in any setting, including LMICs. Two well-
established associations were chosen: risk of aseptic meningitis
(AM) following first dose of mumps-containing vaccines [9–11],
and risk of immune thrombocytopenic purpura (ITP) following first
dose of measles-containing vaccines [8,12–14].2. Methods
International hospital-based retrospective observational study
conducted as proof-of-concept for the investigation of rare AEFI
using two analytical case-only methods: self-controlled risk inter-
val (SCRI) and case-crossover [15,16]. For this purpose, WHO
selected 26 sentinel sites (49 hospitals) distributed in 16 countries
of the six WHO regions (Fig. 1). Selection criteria and capability
assessments are described elsewhere (Bravo-Alcántara P, Perez-
Vilar S, Molina-León HF et al. (accepted for publication in Vaccine
[45])).2.1. Study population
The study population included children ages 9–23 months
admitted to a network-participating hospital during January
2010-March 2014, with a discharge diagnosis of either AM or ITP.
Only individuals living in the pre-defined catchment area of the
hospital, or, for those hospitals without a pre-specified catchment
area, in the same city in which the hospital was located, were
eligible.Participating hospitals identified potential cases through hospi-
tal discharge databases using pre-specified ICD-9/ICD-10 codes
(Supplementary material; Table S-1) whereas hospitals not using
a discharge codification system or not having electronic databases
used free text. A trained physician or nurse blinded to vaccination
status reviewed medical records of potential cases according to
established case definitions (Supplementary material; Tables S-2
and S-3). Potential cases for which medical records were not avail-
able were excluded. Only first episodes of AM or ITP were
considered.
Potential AM cases were excluded if they met criteria for
encephalitis [17] (Supplementary material; Table S-4), the medical
records showed that a physician ruled out a diagnosis of AM, a
meningitis pathogen other than mumps virus was identified in
cerebrospinal fluid (CSF), CSF protein concentration (in absence
of traumatic lumbar puncture or intracerebral event) was
50 mg/dL with 10 leukocytes/mm3 and glucose 40 mg/dL in
CSF, or if polymorphonuclear leukocytes (PMNs) in the CSF were
>1000/mm3 with glucose 40 mg/dL (modified from Lussiana
et al.) [18].
Potential ITP cases were excluded if classified as chronic
(defined as lasting >6 months) [12,14], with onset of symptoms
occurring >42 days prior to hospital admission, or if a physician
diagnosis in the medical records ruled out the diagnosis of ITP or
thrombocytopenia. ITP cases with medical conditions associated
with higher ITP risk (congenital/hereditary thrombocytopenia,
aplastic anemia, defibrination syndrome, acquired hemolytic ane-
mia, chronic liver disease, malignancy, or drug-induced thrombo-
cytopenia) were also excluded. For the analyses presented here,
patients treated with platelet-depleting medications (amiodarone,
heparin, carbamazepine, phenytoin, valproic acid, quinidine, qui-
nine, rifampicin, ethambutol, sulfisoxazole, vancomycin, ampi-
cillin, trimethoprim-sulfamethoxazole, naproxen, or ranitidine)
during hospitalization or in the 42 days prior, unless there was evi-
dence that the drug was administered after disease onset date,
were also excluded.
All cases were classified as either confirmed (Level 1–3 of diag-
nosis certainty) or non-confirmed (Supplementary material; Tables
S-2 and S-3). Only confirmed cases entered the analyses.
The event date for AM cases was onset date of signs and symp-
toms suggestive of meningitis, admission date, or date of first
physician diagnosis, whichever occurred earlier. The event date
for ITP cases was onset date of spontaneous bleeding [19], date
of first laboratory result with a platelet count <50,000/lL per-
formed within 42 days prior to hospital admission or during hospi-
talization, admission date, or date of first physician diagnosis,
whichever occurred earlier.2.3. Vaccination status
Vaccination status was retrieved, for confirmed cases only, from
vaccine registries, vaccination cards, and medical records. The
exposure of interest was first dose of measles/mumps-containing
vaccine. Patients were considered as non-vaccinated when any
other vaccinations, but not measles-containing vaccines, were reg-
istered in the consulted sources. Individuals without any vaccina-
tion record were excluded from the study.2.4. Data collection and sharing
Sites collected data using a common protocol, and transferred
them into electronic case report forms using the purpose-built
Fig. 1. Geographical distribution of participating hospitals in the WHO regions. Disclaimer: Lines on the map represent approximate border lines for which there may not yet
be full agreement.
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lands). Chameleon classified the cases automatically according
to their level of diagnostic certainty. Outcome and exposure-
coded datasets containing non-identifiable time interval-only data
created by Chameleon were uploaded to a central remote
research environment, located at EMC, through a secure
connection.
2.5. Quality assurance
In parallel with the study protocol and manual of procedures, a
quality assurance plan was developed. It included roles and
responsibilities for feasibility assessment, protocol development,
data collection/transformation, analysis and reporting. The coordi-
nation team trained investigators through on-site and/or virtual
meetings and through a simulation exercise using dummy cases,
reviewed data submitted using standardized procedures, and sent
reports to the sites detailing inconsistencies and missing data
found. Following these communications, sites were asked to sub-
mit final data for analyses. Detailed information on quality assur-
ance activities implemented and operating procedures followed
for data collection, entry, and submission can be found elsewhereTable 1
Measles and mumps strains included in the vaccine products used by the participating co
Vaccine product
Priorix, GlaxoSmithKline Biologicals
Priorix Tetra, GlaxoSmithKline Biologicals
MMR, Shanghai Institute of Biological Products, Co., Ltd
Measles, Lanzhou Institute of Biological Products Co., Ltd
Measles-Rubella, Beijing Tiantan Biological Products, Co., Ltd
M-M-R-II, Merck Sharp & Dohme Corp.
MMR, Razi Vaccine and Serum Research Institute
M-M-RVAXPRO, Sanofi Pasteur-MSD
Trimovax, Sanofi Pasteur
Measles, Serum Institute of India Pvt. Ltd
Measles-Rubella, Serum Institute of India Pvt. Ltd
MMR, Serum Institute of India Pvt. Ltd
Tresivac, Serum Institute of India Pvt. Ltd
Rouvax, Sanofi Pasteur
Abbreviations: MMR (measles-mumps-rubella).
a Derived from Jeryl Lynn strain.(Bravo-Alcántara P, Perez-Vilar S, Molina-León HF et al. (accepted
for publication in Vaccine [45])).2.6. Statistical analyses
The risks of AM following mumps-containing vaccination and
ITP following measles-containing vaccination were estimated
using self-controlled risk interval (SCRI) analyses [15,20,21]. The
observation period started on the day following first-dose vaccina-
tion and ended on day 84 post-vaccination. Days 8–35 were con-
sidered the risk period, days 1–7 and 36–42 washout periods,
and days 43–84 the non-risk period. Thus, only vaccinated cases
for which the event occurred within 84 days following vaccination
were included. Poisson regression conditioned on the fact that the
event occurred was used to estimate the incidence rate ratio. Dif-
ferential risk of AM and ITP in the risk and non-risk windows
due to circulation of wild viruses linked to the diseases of interest
and age were adjusted for in the models as follows: (1) cut-off
points for seasonality were March 31, June 30, September 30,
and December 31; (2) age was controlled for with periods ending
at 365, 457, 549, 641 days, and 732 days of age.untries during the study period.
Measles strain Mumps strain
Schwarz RIT 4385a
Schwarz RIT 4385a
Shanghai-191 S79
Shanghai-191 –
Shanghai-191 –
Enders’ Edmonston Jeryl Lynn (Level B)
AIK-C Hoshino
Enders’Edmonston Jeryl Lynn (Level B)
Schwarz Urabe Am9
Edmonston-Zagreb –
Edmonston-Zagreb –
Edmonston-Zagreb Leningrad-Zagreb
Edmonston-Zagreb Leningrad-Zagreb
Schwarz –
Table 2
Characteristics of participating sentinel sites.
Sitea Beds Case ascertainment Vaccination status ascertainment Common outcome-exposure identifier Confirmed aseptic
meningitis casesb
Confirmed ITP casesb
(n) ICD
codes
Free
text
Electronic
vaccine registry
Vaccination
cards
Medical
records
Parents
contactedc
Unique
identification
number
Clinical history
number
National
identity card
Level 1
(n)
Level 2
(n)
Level 3
(n)
Level 1
(n)
Level 2
(n)
Level 3
(n)
Albania 240 ICD-9 – U U – – – U – 1 – – 5 – –
Argentina-01 330 ICD-10 – U – – U – U U 1 – – 6 – 1
Argentina-02 78 ICD-10 – U – – U – U U – – – 1 – –
Argentina-03 380 ICD-10 – U – U U – U U – – – 4 – –
Argentina-04 246 ICD-10 – U – – – – U U – – – – – –
Argentina-05 224 ICD-10 – U – – – – U U – – – 4 – –
Argentina-06 61 ICD-10 – U – – U – U U – – – 2 – –
Australia-01 334 ICD-10 – U – – – U U – 2 5 – 5 – 2
Australia-02 184 ICD-10 – U U – – U U – – – 1 4 – –
Chile-01 440 ICD-10 – U – – – – – U 3 – – 2 – –
Chile-02 300 ICD-10 – U – – U – – U 5 – 1 4 – –
Chile-03 704 ICD-10 – U – – – – – U – – – 6 – –
Chile-04 876 ICD-10 – U – – U – – U – 1 – 5 – –
China 500+ ICD-10 – U – – – – – – – – 1 7 – –
Colombia 340 ICD-10 – U – – – – – U – – – 2 – –
Costa Rica 313 ICD-10 – U – – U – – U 1 2 1 13 – –
Honduras 1109 ICD-10 – – – U U – U U – – – 1 – –
India 1200 ICD-9, ICD-10 – – – U U U – – 3 5 – 1 1 –
Iran-01 246 ICD-10 – – – U – – – – 8 16 2 14 3 –
Iran-02 340 ICD-10 – – – U U – – – 9 6 1 20 – –
Peru 465 ICD-10 – – – U U – – U – – – 7 – –
Singapore 830 ICD-9, ICD-10 – U – U – U U U – – – 17 1 2
South Africa 3200 ICD-10 – – – U U – – – – 1 2 – – –
Spaind 10,987 ICD-9 – U – – – U – – 2 – 3 32 2 6
Uganda 254 – U – U U U – – – – – – – – –
Uruguay 245 ICD-10 – U – – – – – U 1 – – 3 – –
a The study period was January 2010 to March 2014, except for Australia, which retrospectively included the first 25 most recent cases that fulfill inclusion criteria for each condition (for both sites combined).
b Only the highest level of diagnosis certainty achieved applies. The cases correspond to confirmed cases for which a link to vaccination data was available. Confirmed cases for which vaccination status was unknown were
excluded from the study.
c Parents contacted were asked to provide a copy of the vaccination cards.
d Spain was designated as one site, but included all public hospitals of the Valencia Region, its hospital beds correspond to the total number of beds from the combined hospitals.
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Table 3
Characteristics of children with confirmed aseptic meningitis or immune thrombo-
cytopenic purpura (ITP).
Characteristic Confirmed aseptic
meningitis cases n = 84
Confirmed ITP
cases n = 183
Male sex (n, %) 54 (64%) 98 (54%)
Age at onset in months
(median; IQR)
13 (12–15) 15 (12–19)
Mumps-containing first dose
vaccination (n, %)
80 (95%) –
Exact date known (n, %) 60 (75%) –
Vaccine brand known (n, %) 41 (51%) –
Age at vaccination in months
(median; IQR)
12 (11–12.5) –
Measles-containing first
dose vaccination (n, %)
– 172 (94%)
Exact date known (n, %) – 159 (92%)
Vaccine brand known (n, %) – 125 (73%)
Age at vaccination in months
(median; IQR)
– 12 (12–15)
Two aseptic meningitis cases died during the observation period, one case in Spain
78 days after disease onset date and another case in Australia 608 days following
disease onset. None ITP case was known to die during the observation period.
as
es
Jeryl-Lynn
Hoshino,Leningrad-Zagreb,UrabeAM9
3
4
0
1
2
3
4
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analysis [22]. The observation period was 84 days prior to event
occurrence (case window: days 1 to 42; control window: days
43 to84). Thus, cases without at least 84 days of follow-up prior
to the event were excluded, regardless of vaccination status. The
risk periods were days 8 to 35 for the case window and days
50 to 77 for the control window. The remaining periods were
considered washout periods. Crude odds ratios were estimated
using conditional logistic regression.
One site did not collect complete vaccination dates for any of
the confirmed cases; thus, the day of vaccination was randomly
imputed by Chameleon within the month and year provided.
Because of the importance of having exact vaccination dates for
case-only methods, analyses with and without cases from this site
(Iran-01) were performed.
Because the risks for AM and ITP may vary by virus strain, [8–
11,23–25], exploratory analyses were performed by mumps and
measles strain received, respectively. The two participating Iranian
sites reported that three measles-mumps-rubella (MMR) vaccines,
manufactured by Razi Vaccine, Serum Institute of India and Sanofi
Pasteur, were used in the country during the study period, but they
could not identify which specific product was administered to an
individual patient. Thus, a separate analysis for the two Iranian
sites was also conducted. Measles/mumps strains included in the
vaccine products used by participating countries are shown in
Table 1.
All analyses were conducted using SAS 9.4 (SAS Institute, Inc.,
Cary, NC). The WHO Ethics Review Committee and all local Ethics
Committees approved the study and provided a waiver of informed
consent according to article 32 of the Declaration of Helsinki [26].
Given the need for accurate information on vaccination status, a
waiver to contact parents or legal representatives in case of lack
of vaccination information was also obtained.N
o 
of
 c
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Fig. 2a. Interval between first dose of mumps-containing vaccines and aseptic
meningitis onset by mumps vaccine strain. Only aseptic meningitis cases with onset
on days 0 to 84 are shown. Cases from Iran01 for which exact vaccination dates
were unavailable were excluded. Mumps strain used in the Iranian sites was either
Hoshino, Urabe Am9 or Leningrad-Zagreb.3. Results
A total of 84 confirmed AM cases and 183 confirmed ITP cases
were eligible for inclusion in the case-only analyses. Number of
confirmed cases successfully linked to vaccination records by site/-
country, level of diagnosis certainty, and site characteristics,
including case ascertainment methods, vaccination data sources,
and identifiers used to link exposures and outcomes, are shown
in Table 2.
Among 84 AM cases, 80 (95%) received a first dose of mumps-
containing vaccines (Table 3). A total of 51 (61%) and a total of
73 (87%) were eligible for inclusion in the SCRI and case-
crossover analyses, respectively. The risk of AM following mumps
containing vaccines was 10.9 (95% CI 4.2–27.8) with the SCRI anal-
ysis. Sensitivity analyses excluding Iran-01 resulted in an IRR esti-
mate of 11.7 (95% CI 3.5–39.3). Intervals between first dose of
mumps-containing vaccine and aseptic meningitis onset for cases
included in the strain-specific SCRI analyses are shown in Fig. 2a.
A significantly increased AM risk was found for the Leningrad-
Zagreb mumps strain (IRR: 10.8; 95% CI: 1.3–87.4). Risk estimates
for S79, UrabeAm9 and RIT 4385/Jeryl-Lynn strains could not be
assessed given small numbers. For the vaccine products used in
Iran (Hoshino/Leningrad-Zagreb/UrabeAm9), an IRR of 20.3 (95%
CI: 4.8–85.2) was identified (Table 4). Case-crossover analysis pro-
duced an overall unadjusted OR of 35.0 (95% CI: 4.8–255.5). When
cases from Iran-01 were excluded, the OR estimate was 22.0 (95%
CI: 3.0–163.2).
Among 183 ITP cases, 172 (94%) were vaccinated with first dose
of measles-containing vaccines. Of them, 55 (30%) and 152 (83%)
were eligible for inclusion in the SCRI and case-crossover analyses,
respectively. The risk of ITP following measles vaccination was 5.0(95% CI: 2.5–9.7); exclusion of cases from Iran-01 resulted in an IRR
estimate of 7.7 (95% CI: 3.5–17.3). Intervals between first dose of
measles-containing vaccine and ITP onset for cases included in
the strain-specific SCRI analyses are shown in Fig. 2b. This analysis
showed a significantly elevated ITP risk for measles vaccines con-
taining Schwarz (IRR: 20.7; 95% CI: 2.7–157.6), Edmonston-
Zagreb (IRR: 11.1; 95% CI: 1.4–90.3), and Enders’Edmonston (IRR:
8.5; 95% CI: 1.9–38.1) strains. Risk estimates for Shanghai-191
could not be assessed because of small numbers. Our estimates
for the vaccine product/s used in Iran (AIK-C/Edmoston-Zagreb/
Schwarz) did not show an increased risk of ITP (IRR: 0.51; 95%
CI: 0.10–2.54) (Table 4). The case-crossover analysis produced an
Table 4
Risk of aseptic meningitis following mumps-containing vaccination and risk of immune thrombocytopenic purpura (ITP) following measles-containing vaccination; overall and by
vaccine strain.
Mumps vaccine straina SCRI analyses
Event in risk period
(8–35 days)
Event in non-risk period
(43–84 days)
Median (P25-P75) Unadjusted (95% CI) Adjusted 95% CI
Follow-up (days) Relative incidence (IRR)
Eligible confirmed aseptic meningitis casesb
Overall 35 5 85 (85, 85) 10.9 (4.2–27.8) 10.8 (4.0–29.2)
Overallc 22 3 85 (85, 85) 11.7 (3.5–39.3) 12.4 (3.1–49.1)
Hoshino/Leningrad-Zagreb/UrabeAm9 27 2 85 (85, 85) 20.3 (4.8–85.2) Non-estimable
Hoshino/Leningrad-Zagreb/UrabeAm9c 14 0 85 (85, 85) Non-estimable Non-estimable
Leningrad-Zagreb 7 1 85 (85, 85) 10.8 (1.3–87.4) 6.4 (0.3–124.4)
RIT 4385/Jeryl Lynn (Level B) 0 1 85 (85, 85) Non-estimable Non-estimable
Eligible confirmed ITP casesb
Overall 36 12 85 (70, 85) 5.0 (2.5–9.7) 5.6 (2.7–11.9)
Overallc 36 8 85 (70, 85) 7.7 (3.5–17.3) 9.1 (3.7–22.3)
AIK-C/ Edmonston-Zagreb /Schwarz 2 5 85 (85, 85) 0.51 (0.10–2.54) 0.54 (0.08–3.55)
Edmonston-Zagreb 7 1 85 (67, 85) 11.1 (1.4–90.3) 8.4 (0.7–100.3)
Enders’Edmonston 11 3 85 (43, 85) 8.5 (1.9–38.1) 28.7 (1.9–443.5)
Schwarz 14 1 85 (76, 85) 20.7 (2.7–157.6) Non-estimable
Shanghai-191 0 1 85 (85, 85) Non-estimable Non-estimable
a There were no cases within days 8–35 or days 43–84 following first dose vaccination with mumps strains S79 or Urabe Am9.
b The remaining cases occurred during the washout periods (days 1–7, days 36–42 following vaccination).
c Excluding cases from Iran-01 since this site did not provide exact vaccination dates.
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Fig. 2b. Interval between first dose of measles-containing vaccines and immune
thrombocytopenic purpura) ITP onset by measles vaccine strain. Only ITP cases
which onset on days 0-84 days are shown. Cases from Iran01 for which vaccination
dates were imputed were excluded. Cases that received platelet depleting medi-
cation were excluded.
352 S. Perez-Vilar et al. / Vaccine 36 (2018) 347–354overall unadjusted OR of 4.7 (95% CI: 2.1–10.7). When cases from
Iran-01 were excluded, the OR estimate was 6.6 (95% CI: 2.6–16.9).4. Discussion
The success of this proof-of-concept study in obtaining partici-
pation and data useful for analysis from sites located in all regionsof the world using a common protocol has demonstrated the feasi-
bility of international collaborative hospital-based studies, with
high participation of LMICs, for the investigation of serious and
rare AEFI. Moreover, the study has confirmed increased risks of
AM following first dose of mumps-containing vaccines, and of ITP
following first dose of measles-containing vaccines. It has also
shown, potential risk differences between vaccine strains for both
associations. The elevated risk estimates found for the Leningrad-
Zagreb mumps strain are consistent with previous studies
[27,28]. Regarding Jeryl-Lynn-derived strain vaccines, although
the study did not have enough power to confirm the absence of risk
for these strains, our finding of zero cases in the risk window was
consistent with the hypothesis of no association [25,29]. The two
Iranian sites reported that three vaccine products, containing the
mumps strains Hoshino, Leningrad-Zagreb and UrabeAm9 were
used during the study period, but they did not differentiate
between them. Therefore, we could not assign the high risk of
AM identified in Iran to one or other of these three strains
[23,24,27,28,30–32]. This would require further investigation in
subsequent studies, particularly to determine the risk associated
with the Hoshino strain, given the limited literature available on
its safety profile [33–36]. AM usually occurs within 2–5 weeks fol-
lowing mumps vaccination [9,11,31,32,37,38]; therefore, our study
used a risk window of 8–35 days post-vaccination. Our study found
a statistically significant risk when the washout period (days 1–7
and days 36–42 post-vaccination) was compared to the non-risk
periods (days 43–84 post-vaccination) for the vaccine/s products
used in Iran (IRR: 12.9; 95% CI: 2.8–59.7), which suggests the pos-
sibility of an increased risk also for the washout period, that
deserves investigation in future studies.
Theelevatedriskof ITP followingmeasles-containingvaccination
is consistent with the literature [12–14]. Our strain-specific unad-
justed analysis showed a significantly elevated ITP risk for measles
vaccines containing the Schwarz, Edmonston-Zagreb, and
Enders’Edmonston strains. No risk of ITP was identified in Iran,
which reported the concurrent distribution of three vaccine prod-
ucts including the AIK-C, Edmonston-Zagreb and Schwarz strains,
without distinguishing between them. Among 172 vaccinees
included in this study, at least 155 (90%) received MMR or
measles-rubella vaccines. Given the known association between
wild rubella infection and ITP [39], and the existence of a few studies
S. Perez-Vilar et al. / Vaccine 36 (2018) 347–354 353showing mostly mild thrombocytopenia following rubella vaccina-
tion in some adults [19,40–42], a potential contribution of the
rubella component of the vaccine to our findings may not be
excluded.
Case-only methods can be efficient epidemiological designs for
use in vaccine safety, particularly for LMICs, given that population
denominators or separate controls are not required; moreover,
time-fixed confounders are inherently adjusted for [16]. Self-
controlled case series (SCCS) methods have been successfully
implemented in similar international collaborations, such as the
hospital-based international collaborative investigation of
Guillain-Barre syndrome following the H1N1 2009–2010 pan-
demic influenza vaccination [7], and the investigation of the asso-
ciation between intussusception and rotavirus in Mexico and Brazil
[43]. In our study, some of the participating sites could not identify
end of the follow-up period independently of the event being
investigated, thus, modifying the duration of the observation per-
iod in ways that could potentially bias results [44]. The SCRI
approach simplifies the SCCS design by reducing the length of
the control interval [21]. The selection of shorter non-risk periods,
as done in our study under the assumption that participants were
not lost to follow-up during this 84-day period, not only may solve
this limitation for LMICs, but may also decrease the effect of time-
varying confounders on the risk estimates, because risk variations
in such a short period may be negligible [21]. Nonetheless, adjust-
ments for age group and seasonality were performed, when possi-
ble. For comparison purposes, we used case-crossover as a
secondary analysis, given that it does not require follow-up after
case occurrence; to decrease the possibility of bias associated with
variations in the distributions of exposures over time, only one
control window of the same duration as the case window was
selected [16]. The method requires the same underlying probabil-
ity of vaccination in all time intervals, which is unlikely to hold
true for pediatric vaccines, which are usually administered accord-
ing to pre-specified schedules [16]. However, our case-crossover
unadjusted risk estimates for ITP following measles-containing
vaccines and for AM following mumps-containing vaccines were
comparable to those obtained using the SCRI method, although
the latter estimate was less stable due to limited study power.
Case-only methods demand careful determination of event
onset and vaccination dates. Therefore, we were particularly thor-
ough in training site investigators. Given that one site could not
provide exact vaccination dates (only month/year of vaccination
were recorded), we performed analyses both excluding and includ-
ing this site (using imputed dates for the site). Although these anal-
yses showed differences in point estimates, all results were
significant and the confidence intervals overlapped. Since SCRI
uses data only from vaccinees, the approach minimizes potential
misclassification due to incomplete/absent data on vaccination sta-
tus, another frequent shortcoming in LMICs. Nonetheless, a possi-
ble limitation in the approach used here is that site variability
may be a potential source of selection bias as the sites may have
differences in access to vaccination records and in patient’s
health-seeking behavior. Bias could also be associated with site dif-
ferences in diagnosis capabilities and quality of medical records.
Also, our use of self-controlled analytical methods did not permit
estimations of absolute risk [20].
Our results show that collaborative studies for the investigation
of different vaccine products by strain and potentially by manufac-
turer are feasible. The power to do so, and to investigate risk by
country/region (Supplementary material; Tables S-5 and S-6) will
increase when additional large hospitals with medical specialties
for rare and difficult to diagnose events, high quality medical
records and easy access to vaccination records are included [2].
The inclusion of large referral hospitals with electronic discharge
databases should decrease per case investigation costs by reducingefforts associated with data extraction, study coordination, train-
ing, data quality assessment, and provide quality medical records
and higher reliability in disease codification. The use of large hos-
pitals would also reduce the likelihood of having participating hos-
pitals that do not contribute cases to the analysis, as has occurred
in some of our sites. Because easy and unequivocal linkages
between hospital and vaccination records and proven access to
vaccination information would increase data quality and efficiency,
it is important to carefully select the participating sites, particu-
larly in LMICs. Given the current interest on the development of
vaccines for diseases such as dengue, malaria, and Zika, prioritiza-
tion should be given to the addition of sites from tropical/sub-
tropical areas in LMICs for future studies.
5. Conclusions
This collaboration has demonstrated, for the first time, that a
multi-country hospital-based network with high participation of
LMICs, using a common protocol and standardized procedures,
permits the investigation of rare vaccine adverse events, can pro-
duce reliable results, and has the potential to characterize risk dif-
ferences between vaccine strains. The completion of this network
with the addition of large referral hospitals, including from tropi-
cal/subtropical countries, and the systematic implementation of
this hospital-based approach, should permit the rapid and sustain-
able evaluation of safety signals for serious and rare AEFI for new
and existing vaccines in all settings, and the comparison of safety
profiles for vaccine products.
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